Disruptive antibody purification process employing novel inexpensive chromatography materials

采用新型廉价层析材料的破坏性抗体纯化工艺

• 批准号: 104773
• 金额: $ 142.81万
• 依托单位: CELLTECH R&D LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104773
• 关键词: Disruptive; antibody; purification; process; employing

While biotherapeutics offer potential treatments for some of the most debilitating diseases, the development and manufacture of these potentially life changing treatments is risky, technically challenging and expensive. This project will develop novel polymer composite materials specifically for the efficient and cost-effective manufacturing of antibody drugs. This will lead to the replacement of expensive affinity resins with inexpensive small ligand resins reducing the manufacturing cost and increasing purification efficiency. Working in partnership with BioToolomics, UCB Celltech seeks to develop an industrial-scale downstream platform process for monoclonal antibody drugs. The project will utilise modern process development methodology, combined with lifetime studies and cost of goods analysis, to fully explore the potential savings a biotherapeutic manufacturer could make by implementing the novel resins developed in the course of this project.

虽然生物治疗为一些最令人衰弱的疾病提供了潜在的治疗方法，但这些可能改变生活的治疗方法的开发和制造是有风险的，技术上具有挑战性且昂贵。该项目将开发新型聚合物复合材料，专门用于高效和具有成本效益的抗体药物制造。这将导致用廉价的小配体树脂代替昂贵的亲和树脂，从而降低制造成本并提高纯化效率。与BioToolomics合作，UCB Celltech寻求开发单克隆抗体药物的工业规模下游平台工艺。该项目将利用现代工艺开发方法，结合使用寿命研究和商品成本分析，充分探索生物柴油制造商通过实施该项目过程中开发的新型树脂可以实现的潜在节约。